<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395029</url>
  </required_header>
  <id_info>
    <org_study_id>PMD-MSC-PD-01</org_study_id>
    <nct_id>NCT02395029</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD</brief_title>
  <acronym>PMD-MSC-PD-01</acronym>
  <official_title>Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melissa Marchand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Z Urology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open labeled, non-randomized, study to be conducted at a single center. Ten&#xD;
      subjects will undergo an injection of Placental Matrix-Derived Mesenchymal Stem Cells&#xD;
      (PMD-MSCs) into the penis for the treatment of Peyronie's Disease. Follow up visits will be&#xD;
      conducted at 6 weeks, 3 months, 6 months, and 12 months. Subjects will be eligible for&#xD;
      re-injection at 3 months and/or 6 months as determined by the clinician based on patient&#xD;
      reported treatment satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Symptoms of Peyronie's disease include penile pain and curvature of the penis that prevents&#xD;
      penetration and/or causes erectile dysfunction (ED). It is characterized by plaques that form&#xD;
      along the top or bottom side of the penis inside the tunica albuginea; the plaque begins as a&#xD;
      localized inflammation then develops into a hardened scar. Cases can range from mild to&#xD;
      severe. In several cases, the hardened plaque reduces flexibility, causing the penis to curve&#xD;
      during erection. The sexual problems as a result can lower a man's self-esteem and interfere&#xD;
      with a couple's physical and emotional relationship.&#xD;
&#xD;
      The cause is unknown; however, possibilities include trauma, inherited conditions, Vitamin E&#xD;
      deficiency, diabetes, and vascular disease.&#xD;
&#xD;
      Conservative treatments used in the acute phase (initial onset of symptoms) include oral&#xD;
      therapies. Vitamin E and antioxidants can decrease the build-up of harmful chemicals that can&#xD;
      cause injury to tissue. It is often used as the traditional treatment; it is inexpensive and&#xD;
      with proper dosing, there are minimal side effects. Other oral agents include Potaba&#xD;
      (aminobenzoates potassium); however, it is expensive ($1000 per year) and has associated&#xD;
      gastrointestinal side effects.&#xD;
&#xD;
      Other therapies involve injections directly in the plaques (intralesional) with chemicals&#xD;
      such as collagenase or calcium-channel blockers.&#xD;
&#xD;
      Surgical therapies are offered once the disease is stable (symptoms present for one year).&#xD;
      Invasive surgical options consist of correction of the penile curvature or the placement of a&#xD;
      penile prosthesis to straighten the penis to allow for erections.&#xD;
&#xD;
      Mesenchymal stem cells (MSCs) have been used for a variety of medical treatments to repair&#xD;
      and regenerate acute and chronically damaged tissues. These cells have the potential to&#xD;
      repair human tissue by forming cells of mesenchymal origin, such as cartilage, bone, fat,&#xD;
      muscle, and blood vessels. Most research has focused on bone marrow derived stem cells (BMC)&#xD;
      however the process for harvesting the cells is invasive, painful, and yields a low cell&#xD;
      count. The human placenta offers an alternative source form MSCs. Placental Matrix-Derived&#xD;
      Mesenchymal Stem Cells (PMD-MSCs) are compromised of a novel cellular repair matrix derived&#xD;
      from placental mesenchyme. Mesenchyme is the meshwork of embryonic connective tissue in the&#xD;
      mesoderm, from which are formed the muscular and connective tissues of the body and also the&#xD;
      blood vessels. PMD-MSCs provide the extracellular matrix viable mesenchymal stem cells (MSCs)&#xD;
      that coordinate the tissue repair process, regenerative growth factors, and anti-inflammatory&#xD;
      cytokines required to regenerate the damaged vasculature of the penile corpora.&#xD;
&#xD;
      The research proposed here will establish the safety and feasibility of utilizing&#xD;
      intracavernosal, intralesional injections of PMD-MSCs to treat Peyronie's disease with the&#xD;
      intent of avoiding surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass or Fail)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass or Fail)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass or Fail)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass or Fail)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass or Fail)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#1 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#1 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#1 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#1 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#1 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#2 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#2 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#2 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#2 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#2 Penile Plaque (Location) Size (mm^3)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#3 Penile Plaque (Location)Size (mm^3)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#3 Penile Plaque (Location)Size (mm^3)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#3 Penile Plaque (Location)Size (mm^3)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#3 Penile Plaque (Location)Size (mm^3)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>#3 Penile Plaque (Location)Size (mm^3)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Penile Curvature Angle (degrees)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Penile Curvature Angle (degrees)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Penile Curvature Angle (degrees)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Penile Curvature Angle (degrees)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Penile Curvature Angle (degrees)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Peyronie's Disease</condition>
  <arm_group>
    <arm_group_label>Injection of PMD-MSCs into the penis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)</intervention_name>
    <arm_group_label>Injection of PMD-MSCs into the penis</arm_group_label>
    <other_name>Ovation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. acquired penile curvature &gt;15 and &lt;90 degrees associated with palpable penile plaque&#xD;
             on physical examination&#xD;
&#xD;
          2. 1 or 2 penile plaque at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. taking the medication Coumadin&#xD;
&#xD;
          2. unable to achieve adequate erection with penile injection to access degree of&#xD;
             curvature&#xD;
&#xD;
          3. undergone definitive treatment for prostate cancer, bladder cancer, or other pelvic&#xD;
             malignancies including surgery, external beam radiation therapy, brachytherapy,&#xD;
             cryotherapy&#xD;
&#xD;
          4. prior history of prostate cancer, hematologic disorders, chronic liver disease&#xD;
             including cirrhosis and hepatitis C, disorders affecting the immune system, including&#xD;
             infection with the human immunodeficiency virus, or psychiatric disorder including&#xD;
             major depression, schizophrenia, bipolar disease&#xD;
&#xD;
          5. history of cerebrovascular accident, history of deep venous thrombosis within the past&#xD;
             5 years or history of untreated or severe sleep apnea&#xD;
&#xD;
          6. clinically significant abnormal lab results that would put the subject at increased&#xD;
             risk or compromise the integrity of the study data, in the opinion of the investigator&#xD;
&#xD;
          7. received any other investigational drug within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Zahalsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Z Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Z Urology</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Z Urology</investigator_affiliation>
    <investigator_full_name>Melissa Marchand</investigator_full_name>
    <investigator_title>PA-C</investigator_title>
  </responsible_party>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

